Andrew C. Hooker, PhD, is a Professor of Pharmacometrics at Uppsala University, Sweden. Andrew received a BS in Physics with a Mathematics Minor at the University of Colorado and received a Masters and then a PhD in Bioengineering from the University of Washington, Seattle. Andrew joined the faculty at Uppsala University in 2006. His research ranges between methodological and applied pharmacometrics, including: optimal (adaptive) experimental design, methodological problems associated with building, evaluating and using pharmacometric models (including using models for bioequivalence evaluation) and the development and use of PKPD models in a range of therapeutic areas and drug classes. Andrew is a co-developer of a number of software programs including Xpose, PsN, Pharmpy and the optimal design program PopED. Andrew has published over 90 papers in peer reviewed journals, supervised 12 students to their PhD degree and mentored 11 post-docs. In 2012, he co-founded the model-informed drug development consultancy company Pharmetheus.

Dr. Alexander Kulesza is currently Principal Scientist and Lead of Systems Pharmacology at ESQlabs GmbH, Saterland, Germany operating out of Lyon, France. He is also affiliated with the University of Namur, Belgium. After completing his theoretical and computational chemistry Diplom at the Humboldt-University Berlin, he obtained his PhD from the Free University Berlin studying inorganic - biomolecular hybrid systems by ab-initio quantum chemistry methods and molecular dynamics. He then moved to Lyon, France focusing on integrating advanced molecular dynamics techniques like replica-exchange and Free-Energy methods to integrate gas-phase structural biology experiments data for elucidating structurally disordered proteins. Alexander then moved out of fundamental reasearch into drug development joining Novadiscovery (now Nova In silico) as Scientist, then team leader then executive manager and since then working on quantitative systems pharmacology modeling combined with physiologically based pharmacokinetics in inflammatory, immune, infectious, metabolic disorders and (immuno)oncology with a focus on model credibility assessment for potential regulatory applications.

Dr. Androulakis is a Biomedical Engineering, Chemical & Biochemical Engineering Professor at Rutgers University. He is also a graduate faculty member in the Pharmaceutical Sciences as the Ernest Mario School of Pharmacy at Ritegrs University. He received his BS in Chemical Engineering from NTUA and his MS and Ph.D. from Purdue University. He was a research associate at Princeton University before joining ExxonMobil’s Corporate Strategic Research Laboratories. In 2004 he moved back to academia. He is a fellow of the American Institute of Medical and Biological Engineering and a Fellow of the American Institute of Chemical Engineers. He currently chairs the Quantitative Systems Pharmacology Special Interest Group of the International Society of Pharmacometrics. He has published extensively in quantitative systems biology and quantitative systems pharmacology.

Dr. Limei Cheng is an accomplished scientist with 20 years of experience in developing novel algorithms, modeling and simulations for healthcare applications such as quantitative systems pharmacology (QSP). She is currently the QSP Lead of Clinical Pharmacology and Pharmacometrics at (CP&P) at Incyte Corporation in Delaware. In her position, Dr Cheng uses model-based QSP approaches to integrate clinical and non-clinical data in a quantitative and mechanistic way to generate actionable predictions. Prior to joining Incyte, she led QSP-CV group in the department of CP&P at Bristol Myers Squibb (BMS) for almost 8 years. Prior to working at BMS, she spent 3+ years working at Philips Research North America in the Department of Clinical Decision Support Solutions. She began her career as a research associate at the Biomedical Simulation Resource (BMSR) in the Department of Biomedical Engineering at the University of Southern California (USC). Dr. Cheng has numerous recent presentations and publications demonstrating the utility of Systems Pharmacology in Pharmaceutical R&D. Dr. Cheng earned a B.E. in Biomedical Electronic Engineering from Xi’an Jiao Tong University, an M.S. in Electrical Engineering from the University of California, Los Angeles (UCLA), and a Ph.D. in Biomedical Engineering from USC. Her key areas of interest include QSP modeling, pharmacometrics, virtual population simulation, machine learning and AI, and personalized precision medicine.

Sergey Aksenov, a PhD in Physics from Moscow State University, is currently Head of Modeling and Simulation at Arvinas. He spearheads PKPD and pharmacometrics modeling for all PROTAC projects from discovery through confirmatory studies in neurology and oncology. His extensive experience includes translational and early-phase modeling for small molecules, biologics, and gene therapies at Novartis, and serving as Pharmacometrics Science Lead at AstraZeneca. Previously, he was a modeling and simulation scientist at Novartis, focusing on developing drug for neurology and ophthalmology diseases.

Dr. Venkatesh Pilla Reddy is a Senior Director in the Global PKPD and Pharmacometrics group at Eli Lilly and Company in the UK. At Lilly, Venkatesh provides MIDD/PKPD Lead support for projects in oncology ADC and RLT projects and immunology.  He earned his PhD in Pharmacometrics through a collaborative program involving Pfizer, Janssen Pharmaceuticals, and Merck via TI Pharma in the Netherlands. He was a Deputy Topic Leader at ICH, shaping the ICH M12 DDI guideline. He plays a leading role in influential cross-industry working groups, such as IQ TALG, ISOP, ASCPT, and ISSX M&S. 

Piet van der Graaf is Senior Vice President and Head of Applied BioSimulation at Certara, Professor of Systems Pharmacology at Leiden University, and Professor of Pediatrics, Cincinnati Children’s Hospital Medical Center.  From 2013-2016 he was the Director of Research of the Leiden Academic Centre for Drug Research.  From 1999-2013 he held various research leadership positions at Pfizer in Discovery Biology, Pharmacokinetics and Drug Metabolism and Clinical Pharmacology.  He was the founding Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology from 2012-2018 before becoming Editor-in-Chief of Clinical Pharmacology & Therapeutics.  Piet received his doctorate training in clinical medicine with Nobel laureate Sir James Black at King's College London and is a Fellow of the British Pharmacological Society.  He was the recipient of the 2021 Leadership Award from the International Society of Pharmacometrics (ISoP) and the 2024 Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology & Therapeutics (ASCPT).

Prashant Dogra is an Assistant Professor in the Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences at the University of Southern California, where he also serves as Associate Director of the Center for Quantitative Drug and Disease Modeling. He leads interdisciplinary research integrating multiscale mechanistic modeling, quantitative systems pharmacology, and data science to predict in vivo disease dynamics, optimize drug delivery, and support therapeutic development. His work advances the fields of cancer therapeutics, infectious disease vaccines, and nanomedicine by providing innovative modeling tools to accelerate clinical translation. He is particularly enthusiastic about integrating artificial intelligence with mechanistic modeling approaches and currently serves as Principal Investigator on an NIH R01 grant focused on developing AI-integrated mechanistic models to advance nanoparticle-based drug delivery systems.